公开(公告)号：US20210054043A1

公开(公告)日：2021-02-25

申请号：US16968967

申请日：2019-02-11

申请人： HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.

发明人： Michal LOTEM ,  Galit MISHAN EISENBERG ,  Emma HAJAJ

IPC分类号： C07K14/705 ,  A61K39/00 ,  A61P35/00

摘要： The invention relates to cancer immunotherapy, particularly to improved therapeutic modalities involving specifically modulating the expression and/or activity of SLAMF6 splice variants. More specifically, embodiments of the invention provide compositions and methods for cancer therapy, including adoptive T cell transfer therapies, cell vaccines and/or polypeptide- based medicaments. In various embodiments, compositions and methods providing selective augmentation of SLAMF6 variant 3 (SLAMF6var3) N expression or activity on T cells and/or tumor cells are provided.